Hemcheck and Biovitos have signed an additional agreement which enables Hemcheck to send out a calling to the extra general shareholders meeting that will decide on the deal, one week later than what is stipulated in the agreement signed on February 7. The last day to send the calling is now set to March 28. The reason is purely administrative.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, acting CEO
Tel: +46 76 108 8191
Email: joen.averstad@hemcheck.com
About Hemcheck
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca,is the Certified Adviser to the company.